Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype (original) (raw)

• Trip, M.D., Cats, V.M., van Capelle, F.J. & Vreeken, J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. 322, 1549–1554 (1990).
  Article CAS Google Scholar
• Lacoste, L. et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92, 3172–3177 (1995).
  Article CAS Google Scholar
• Kabbani, S.S. et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 104, 181–186 (2001).
  Article CAS Google Scholar
• Vanschoonbeek, K. et al. Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation. Thromb. Haemost. 88, 931–937 (2002).
  Article CAS Google Scholar
• Kabbani, S.S. et al. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am. J. Cardiol. 91, 876–878 (2003).
  Article Google Scholar
• Carvalho, A.C., Colman, R.W. & Lees, R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med. 290, 434–438 (1974).
  Article CAS Google Scholar
• Stuart, M.J., Gerrard, J.M. & White, J.G. Effect of cholesterol on production of thromboxane b2 by platelets in vitro. N. Engl. J. Med. 302, 6–10 (1980).
  Article CAS Google Scholar
• Davi, G. et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85, 1792–1798 (1992).
  Article CAS Google Scholar
• Davi, G. et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 97, 953–957 (1998).
  Article CAS Google Scholar
• Cipollone, F. et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106, 399–402 (2002).
  Article CAS Google Scholar
• Wang, T.H., Bhatt, D.L. & Topol, E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J. (2005).
• Salonen, J.T. et al. Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status. Am. J. Clin. Nutr. 53, 1222–1229 (1991).
  Article CAS Google Scholar
• Vericel, E., Januel, C., Carreras, M., Moulin, P. & Lagarde, M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 53, 1046–1051 (2004).
  Article CAS Google Scholar
• Morita, H., Ikeda, H., Haramaki, N., Eguchi, H. & Imaizumi, T. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J. Am. Coll. Cardiol. 45, 589–594 (2005).
  Article Google Scholar
• Berliner, J.A. & Watson, A.D. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353, 9–11 (2005).
  Article CAS Google Scholar
• Podrez, E.A. et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503–38516 (2002).
  Article CAS Google Scholar
• Podrez, E.A. et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277, 38517–38523 (2002).
  Article CAS Google Scholar
• Sun, M. et al. Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: a potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J. Biol. Chem. 281, 4222–4230 (2006).
  Article CAS Google Scholar
• Podrez, E.A. et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105, 1095–1108 (2000).
  Article CAS Google Scholar
• Febbraio, M., Hajjar, D.P. & Silverstein, R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785–791 (2001).
  Article CAS Google Scholar
• Febbraio, M. et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105, 1049–1056 (2000).
  Article CAS Google Scholar
• Tandon, N.N., Lipsky, R.H., Burgess, W.H. & Jamieson, G.A. Isolation and characterization of platelet glycoprotein IV (CD36). J. Biol. Chem. 264, 7570–7575 (1989).
  CAS PubMed Google Scholar
• Hoebe, K. et al. CD36 is a sensor of diacylglycerides. Nature 433, 523–527 (2005).
  Article CAS Google Scholar
• Podrez, E.A., Schmitt, D., Hoff, H.F. & Hazen, S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547–1560 (1999).
  Article CAS Google Scholar
• Kieffer, N. et al. Developmentally-regulated expression of a 78-kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. Biochem. J. 262, 835–842 (1989).
  Article CAS Google Scholar
• Watson, A.D. et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally-oxidized low-density lipoproteins that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597–13607 (1997).
  Article CAS Google Scholar
• Boullier, A. et al. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 46, 969–976 (2005).
  Article CAS Google Scholar
• Simon, D.I. et al. Decreased neointimal formation in Mac1 −/− mice reveals a role for inflammation in vascular repair after angioplasty. J. Clin. Invest. 105, 293–300 (2000).
  Article CAS Google Scholar
• Sarma, J. et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105, 2166–2171 (2002).
  Article Google Scholar
• Huo, Y. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9, 61–67 (2003).
  Article CAS Google Scholar
• Pearce, S.F. et al. Recombinant glutathione _S_-transferase/CD36 fusion proteins define an oxidized low-density lipoprotein–binding domain. J. Biol. Chem. 273, 34875–34881 (1998).
  Article CAS Google Scholar
• Febbraio, M., Guy, E. & Silverstein, R.L. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 2333–2338 (2004).
  Article CAS Google Scholar
• Eitzman, D.T., Westrick, R.J., Xu, Z., Tyson, J. & Ginsburg, D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E–deficient mice. Arterioscler. Thromb. Vasc. Biol. 20, 1831–1834 (2000).
  Article CAS Google Scholar
• Schafer, K. et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler. Thromb. Vasc. Biol. 23, 2097–2103 (2003).
  Article Google Scholar
• Barter, P.J. et al. Antiinflammatory properties of HDL. Circ. Res. 95, 764–772 (2004).
  Article CAS Google Scholar
• Bodart, V. et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ. Res. 90, 844–849 (2002).
  Article CAS Google Scholar
• Philips, J.A., Rubin, E.J. & Perrimon, N. Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science 309, 1251–1253 (2005).
  Article CAS Google Scholar
• Tandon, N.N., Ockenhouse, C.F., Greco, N.J. & Jamieson, G.A. Adhesive functions of platelets lacking glycoprotein IV (CD36). Blood 78, 2809–2813 (1991).
  CAS PubMed Google Scholar
• Englyst, N.A., Taube, J.M., Aitman, T.J., Baglin, T.P. & Byrne, C.D. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 52, 1248–1255 (2003).
  Article CAS Google Scholar
• Huang, M.M., Bolen, J.B., Barnwell, J.W., Shattil, S.J. & Brugge, J.S. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc. Natl. Acad. Sci. USA 88, 7844–7848 (1991).
  Article CAS Google Scholar
• Maschberger, P. et al. Mildly oxidized low-density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J. Biol. Chem. 275, 19159–19166 (2000).
  Article CAS Google Scholar
• Angelillo-Scherrer, A. et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7, 215–221 (2001).
  Article CAS Google Scholar
• Andre, P. et al. CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism. Nat. Med. 8, 247–252 (2002).
  Article CAS Google Scholar
• Prevost, N. et al. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc. Natl. Acad. Sci. USA 102, 9820–9825 (2005).
  Article CAS Google Scholar
• Plow, E.F. et al. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 66, 724–727 (1985).
  CAS PubMed Google Scholar